| Jahr |
| Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study. (Hess, G., et al.) | 2022 |
| Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry. (Tilch, M., et al.) | 2022 |
| Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England. (Petersohn, S., et al.) | 2022 |
